128 related articles for article (PubMed ID: 34955547)
1. Pulmonary Enteric Adenocarcinoma Harboring a BRAF G469V Mutation.
Shimizu D; Yamamoto H; Shien K; Taniguchi K; Miyoshi K; Namba K; Mesaki K; Sugimoto S; Soh J; Yamane M; Toyooka S
Acta Med Okayama; 2021 Dec; 75(6):759-762. PubMed ID: 34955547
[TBL] [Abstract][Full Text] [Related]
2. Differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma with the assistance of next-generation sequencing and immunohistochemistry.
Zhang J; Xiang C; Han Y; Teng H; Li X; Shao J; Zhu L; Han-Zhang H; Ye J; Yu K
J Cancer Res Clin Oncol; 2019 Jan; 145(1):269-279. PubMed ID: 30415301
[TBL] [Abstract][Full Text] [Related]
3. A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.
Wu H; Feng J; Lu S; Huang J
Cancer Med; 2024 May; 13(10):e7305. PubMed ID: 38770647
[TBL] [Abstract][Full Text] [Related]
4. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics.
Salimian KJ; Fazeli R; Zheng G; Ettinger D; Maleki Z
Acta Cytol; 2018; 62(2):79-84. PubMed ID: 29320776
[TBL] [Abstract][Full Text] [Related]
5. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
Reyes R; Mayo-de-Las-Casas C; Teixidó C; Cabrera C; Marín E; Vollmer I; Jares P; Garzón M; Molina-Vila MÁ; Reguart N
Clin Lung Cancer; 2019 May; 20(3):e219-e223. PubMed ID: 30926357
[No Abstract] [Full Text] [Related]
6. A case of a primary lung cancer comprised of adenocarcinoma and atypical carcinoid tumor with both components harboring BRAF p.V600E mutation.
Olofson AM; Tafe LJ
Exp Mol Pathol; 2018 Feb; 104(1):26-28. PubMed ID: 29248665
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
8. VPS41-BRAF, a novel BRAF fusion gene identified in a lung adenocarcinoma patient by next-generation sequencing.
Wang L; Chen A; She X; Xiang J; Tang J
Lung Cancer; 2020 Aug; 146():380-381. PubMed ID: 32527614
[No Abstract] [Full Text] [Related]
9. Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.
Zuo Y; Zhong J; Bai H; Xu B; Wang Z; Li W; Chen Y; Jin S; Wang S; Wang X; Wan R; Xu J; Fei K; Han J; Yang Z; Bao H; Shao Y; Ying J; Song Q; Duan J; Wang J
EBioMedicine; 2022 Aug; 82():104165. PubMed ID: 35901658
[TBL] [Abstract][Full Text] [Related]
10. Lung Cancer Driven by BRAF
Huo KG; Notsuda H; Fang Z; Liu NF; Gebregiworgis T; Li Q; Pham NA; Li M; Liu N; Shepherd FA; Marshall CB; Ikura M; Moghal N; Tsao MS
J Thorac Oncol; 2022 Feb; 17(2):277-288. PubMed ID: 34648945
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
[TBL] [Abstract][Full Text] [Related]
12. Does V600E BRAF mutation predict vinorelbine efficacy? A proof-of-concept from a lung micropapillary adenocarcinoma metastatic to the breast.
Carassai P; Jocollé G; Donati G; Spinazzé S; Baiocco C; Baderna P; Martinet A; Lococo F; Migliaccio F; Rossi G
Pathologica; 2017 Dec; 109(4):426-428. PubMed ID: 29449740
[No Abstract] [Full Text] [Related]
13. Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E Mutation.
Leblond AL; Rechsteiner M; Jones A; Brajkovic S; Dupouy D; Soltermann A
Am J Clin Pathol; 2019 Jun; 152(1):59-73. PubMed ID: 31065676
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
Singh V; Guleria P; Malik PS; Mohan A; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Jain D
Curr Probl Cancer; 2019 Oct; 43(5):391-401. PubMed ID: 30591192
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
[TBL] [Abstract][Full Text] [Related]
16. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and genetic analyses of pulmonary enteric adenocarcinoma.
Okada F; Takeda M; Fujii T; Uchiyama T; Sasaki S; Matsuoka M; Nitta Y; Terada C; Maebo K; Morita K; Ishida E; Sawabata N; Ohbayashi C
J Clin Pathol; 2024 Jan; 77(2):111-115. PubMed ID: 36456172
[TBL] [Abstract][Full Text] [Related]
18. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.
Zheng G; Tseng LH; Chen G; Haley L; Illei P; Gocke CD; Eshleman JR; Lin MT
BMC Cancer; 2015 Oct; 15():779. PubMed ID: 26498038
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous metastasis as a primary presentation of a pulmonary enteric adenocarcinoma.
Todisco A; Internò V; Stucci LS; Ostuni C; Lovero D; D'Oronzo S; Mele F; Duda L; Palmirotta R; Silvestris F
Int J Biol Markers; 2019 Dec; 34(4):421-426. PubMed ID: 31556336
[TBL] [Abstract][Full Text] [Related]
20. Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma.
Xiang C; Ji C; Cai Y; Teng H; Wang Y; Zhao R; Shang Z; Guo L; Chen S; Lizaso A; Lin J; Wang H; Li B; Zhang Z; Zhao J; Wei J; Liu J; Zhu L; Fang W; Han Y
Mod Pathol; 2022 Sep; 35(9):1181-1192. PubMed ID: 35641658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]